Interstitial nephritis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Interstitial nephritis}}
 
{{CMG}} {{AE}}{{M.B}}
{{CMG}} {{AE}}{{M.B}}


==Overview==
==Overview==
The mainstay of treatment for TIN is discontinuation of potentially offending agent, as well as beginning supportive care. The majority of patients involved with drug-induced AIN, improve spontaneously; however, [[renal function]] may not return to previous condition.
The mainstay of treatment for TIN is discontinuation of potentially offending agent, as well as beginning supportive care. The majority of patients involved with drug-induced AIN, improve spontaneously; however, [[renal function]] may not return to previous condition.


No additional measures is needed among patients with minimal rise in the [[serum creatinine]] or those who show betterment after
No additional measures is needed among patients with minimal rise in the [[serum creatinine]] or those who demonstrate betterment after


discontinuation of  offending agent; otherwise if [[renal failure]] persists after removing the culprit drug, obtaining a [[Biopsy|renal  biopsy]] and attempt [[glucocorticoids]] therapy for patients with biopsy-confirmed AIN must be considered.
discontinuation of  offending agent; otherwise if [[renal failure]] persists after removing the culprit drug, obtaining a [[Biopsy|renal  biopsy]] and attempt [[glucocorticoids]] therapy for patients with biopsy-confirmed AIN must be considered.
Line 21: Line 21:
=== Glucocorticoid therapy ===
=== Glucocorticoid therapy ===
* Glucocorticoid therapy is recommended among patients with critical rise in the [[serum creatinine]] , or those whose renal failure persists after removing the offending agents; although before beginning of glucocorticoid therapy obtaining a kidney biopsy and confirm the diagnosis is necessary.
* Glucocorticoid therapy is recommended among patients with critical rise in the [[serum creatinine]] , or those whose renal failure persists after removing the offending agents; although before beginning of glucocorticoid therapy obtaining a kidney biopsy and confirm the diagnosis is necessary.
 
* Preferred regimen: Prednisone 1 mg/kg per day PO or equivalent IV dose (maximum of 40 to 60 mg) for a minimum of one to two weeks, by a gradual taper over 3-4 weeks.


===== First line: =====
* Alternative regimen: In patients who do not respond to corticosteroids within 2-3 weeks, or who are glucocorticoid dependent or  glucocorticoid resistant (as with NSAID-induced disease),  mycophenolate mofetil may be considered.
* Preferred regimen: Prednisone 1 mg/kg per day PO or equivalent IV dose (maximum of 40 to 60 mg) for a minimum of one to two weeks, by a gradual taper over 3-4 weeks.
* The manifestations and diagnosis of AIN and the approach to  the management of patients diagnosed with infection-induced AIN, tubulointerstitial nephritis and uveitis, and renal  sarcoidosis are presented separately.
Lead toxicity: Repeated chelation therapy may improve renal function:
 
Succimer 10 mg/kg PO q8h × 5 days, then q12h × 14 days, or
 
EDTA 2 g IV/IM; if IM, use with 2% lidocaine.
 
SLE nephritis: Steroids +cyclophosphamide or azathioprine
 
Urate nephropathy: Allopurinol to decrease urate level
 
Use with caution because allopurinol is nephrotoxic.
 
Lithium-induced nephritis: Use amiloride as adjunct.


* Alternative regimen: In patients who do not respond to corticosteroids within 2-3 weeks, or who are glucocorticoid dependent or  glucocorticoid resistant (as with NSAID-induced disease),  mycophenolate mofetil may be considered
Cidofovir-induced nephritis: Use probenecid as adjunct


==References==
==References==

Revision as of 05:28, 5 July 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohsen Basiri M.D.

Overview

The mainstay of treatment for TIN is discontinuation of potentially offending agent, as well as beginning supportive care. The majority of patients involved with drug-induced AIN, improve spontaneously; however, renal function may not return to previous condition.

No additional measures is needed among patients with minimal rise in the serum creatinine or those who demonstrate betterment after

discontinuation of offending agent; otherwise if renal failure persists after removing the culprit drug, obtaining a renal biopsy and attempt glucocorticoids therapy for patients with biopsy-confirmed AIN must be considered.

Medical Therapy

The mainstay of treatment for TIN is discontinuation of potentially offending agent, as well as following measures:

  1. Supportive care and maintenance adequate hydration
  2. Symptomatic relief for fever, rash, and systemic symptoms
  3. Control of blood pressure
  4. Correct electrolyte imbalances
  5. Reduce exposure to other nephrotoxic agents

The majority of patients involved with drug-induced AIN, improve spontaneously, and no additional measures is needed among patients with minimal rise in the serum creatinine or those who show betterment after discontinuation of offending agent; otherwise if renal failure persists after removing the culprit drug, obtaining a renal biopsy and attempt glucocorticoids therapy for patients with biopsy-confirmed AIN must be considered.

Glucocorticoid therapy

  • Glucocorticoid therapy is recommended among patients with critical rise in the serum creatinine , or those whose renal failure persists after removing the offending agents; although before beginning of glucocorticoid therapy obtaining a kidney biopsy and confirm the diagnosis is necessary.
  • Preferred regimen: Prednisone 1 mg/kg per day PO or equivalent IV dose (maximum of 40 to 60 mg) for a minimum of one to two weeks, by a gradual taper over 3-4 weeks.
  • Alternative regimen: In patients who do not respond to corticosteroids within 2-3 weeks, or who are glucocorticoid dependent or glucocorticoid resistant (as with NSAID-induced disease), mycophenolate mofetil may be considered.
  • The manifestations and diagnosis of AIN and the approach to the management of patients diagnosed with infection-induced AIN, tubulointerstitial nephritis and uveitis, and renal sarcoidosis are presented separately.

Lead toxicity: Repeated chelation therapy may improve renal function:

Succimer 10 mg/kg PO q8h × 5 days, then q12h × 14 days, or

EDTA 2 g IV/IM; if IM, use with 2% lidocaine.

SLE nephritis: Steroids +cyclophosphamide or azathioprine

Urate nephropathy: Allopurinol to decrease urate level

Use with caution because allopurinol is nephrotoxic.

Lithium-induced nephritis: Use amiloride as adjunct.

Cidofovir-induced nephritis: Use probenecid as adjunct

References

Template:WH Template:WS